ReviewIranian journal of basic medical sciences2023
Hidden attributes of zymosan in the pathogenesis of inflammatory diseases: A tale of the fungal agent.
Review in Iranian journal of basic medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Evasins: Biology and Therapeutic Potential of Broad-Spectrum Chemokine Inhibitors.Basic & clinical pharmacology & toxicology · 2026Review
- Article
- GATA1-deficient human pluripotent stem cells generate neutrophils with improved antifungal immunity that is mediated by the integrin CD18.PLoS pathogens · 2025Article
- GATA1-deficient human pluripotent stem cells generate neutrophils with improved antifungal immunity that is mediated by the integrin CD18.bioRxiv : the preprint server for biology · 2024Article
- Preclinical models of atherosclerosis: An overview.Iranian journal of basic medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation triggers immune system-mediated actions that contribute to the development of multiple diseases. Zymosan, a polysaccharide derived from the Saccharomyces cerevisiae cell wall, is mainly made up of glucan and mannan residues and is used as an inflammatory agent. Zymosan is a fungal product that activates the immune system through the activation of inflammatory signaling pathways, and releases a variety of harmful chemicals including pattern recognition receptors, reactive oxygen species (ROS), and the excitatory amino acid glutamate, cytokines, adhesion molecules, etc. Furthermore, we will dive into the molecular mechanistic insights through which this fungal agent induces and influences various inflammatory diseases such as cardiovascular, neuroinflammation, diabetes, arthritis, and sepsis. Based on the evidence, zymosan appears to be a promising inflammatory-inducing agent. Nonetheless, more animal data is the need of the hour to catch a glimpse and unravel the capacity of zymosan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.